Gilead Fails FDA Approval for 2 HIV Drugs in 4-in-1 Pill

Gilead Sciences Inc. failed to win U.S. regulatory approval to sell as separate products two HIV medicines that are part of its four-in-one pill Stribild.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.